{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:00:26Z","timestamp":1790319626720,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck-Serono"},{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Canbex therapeutics"},{"name":"Sanofi-Genzyme"},{"DOI":"10.13039\/100007449","name":"Takeda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Serono"},{"DOI":"10.13039\/100008976","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008976","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lipomed"},{"name":"Merck Serono"},{"DOI":"10.13039\/100004336","name":"Novartis, Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ECTRIMS Clinical Training fellowship"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.11.001","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T11:49:52Z","timestamp":1541159392000},"page":"247-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies"],"prefix":"10.1016","volume":"27","author":[{"given":"Zhifeng","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1644-3549","authenticated-orcid":false,"given":"C\u00e9sar","family":"\u00c1lvarez-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1207-8625","authenticated-orcid":false,"given":"Kimberley","family":"Allen-Philbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"De Trane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Campion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin P","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-9070","authenticated-orcid":false,"given":"Monica","family":"Marta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmilee","family":"Gnanapavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Espasandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joela","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8872-8711","authenticated-orcid":false,"given":"David","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-8893","authenticated-orcid":false,"given":"Klaus","family":"Schmierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.11.001_bib0001","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1136\/jnnp-2013-306573.170","article-title":"Using routine point\u2013of\u2013care data for research: The East London multiple sclerosis cohort","volume":"84","author":"Albor","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.11.001_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/acn3.410","article-title":"Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis","author":"Alvarez-Gonzalez","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2018.11.001_bib0003","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","article-title":"et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion","volume":"4","author":"Baker","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.11.001_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2018.11.001_bib0049","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1093\/brain\/awy239","article-title":"Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis","volume":"141","author":"Baker","year":"2018","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.msard.2018.11.001_bib0005","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.msard.2018.11.001_bib0006","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40263-016-0394-8","article-title":"Alemtuzumab use in clinical practice: Recommendations from European multiple sclerosis experts","volume":"31","author":"Berger","year":"2017","journal-title":"CNS Drugs"},{"issue":"15 Supplement","key":"10.1016\/j.msard.2018.11.001_bib0007","article-title":"Safety and efficacy of IV cladribine versus alemtuzumab in aggressive multiple sclerosis: A retrospective cohort study (P1.368)","volume":"90","author":"Bose","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.001_bib0008","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1212\/WNL.0000000000002745","article-title":"Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study","volume":"86","author":"Buttmann","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.001_bib0009","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-018-8830-y","article-title":"Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells","author":"Ceronie","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.11.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1352458517717811","article-title":"Disease modification in advanced MS: Focus on upper limb function","author":"Dubuisson","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.11.001_bib0011","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2018.11.001_bib0012","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.001_bib0013","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.msard.2017.01.007","article-title":"Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses","volume":"12","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2018.11.001_bib0014","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/jca.21219","article-title":"Neurologic indications for therapeutic plasma exchange: 2011 update","volume":"27","author":"Gwathmey","year":"2012","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.msard.2018.11.001_bib0015","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.11.001_bib0016","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.001_bib0017","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.11.001_bib0018","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2018.11.001_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/hon.2271","article-title":"Long-term safety and activity of cladribine in patients with extranodal B-cell marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"35","author":"Kiesewetter","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.msard.2018.11.001_bib0020","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2018.11.001_bib0021","article-title":"Cyclophosphamide for multiple sclerosis","author":"La Mantia","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.msard.2018.11.001_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","article-title":"Oral Cladribine for Early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.","volume":"13","author":"Leist","year":"2014","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.msard.2018.11.001_bib0023","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","article-title":"The clinical pharmacokinetics of cladribine","volume":"32","author":"Liliemark","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.msard.2018.11.001_bib0024","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","article-title":"On the bioavailability of oral and subcutaneous 2-chloro-2\u2032-deoxyadenosine in humans: Alternative routes of administration","volume":"10","author":"Liliemark","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2018.11.001_bib0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.msard.2018.11.001_bib0047","article-title":"Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?","volume":"4","author":"Mao","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.msard.2018.11.001_bib0026","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","article-title":"Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology","volume":"130","author":"Magliozzi","year":"2007","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2018.11.001_bib0027","article-title":"Mitoxantrone for multiple sclerosis","author":"Martinelli Boneschi","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2018.11.001_bib0028","doi-asserted-by":"crossref","first-page":"e11337","DOI":"10.1371\/journal.pone.0113371","article-title":"Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: A multicentre randomized non-inferiority trial","volume":"9","author":"Massacesi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.11.001_bib0029","unstructured":"Mavenclad\u00ae - Summary of product characteristics, (http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004230\/WC500234561.pdf)."},{"key":"10.1016\/j.msard.2018.11.001_bib0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.001_bib0031","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.nurt.2007.08.003","article-title":"Immunosuppressive agents in multiple sclerosis","volume":"4","author":"Neuhaus","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.msard.2018.11.001_bib0033","first-page":"336","article-title":"Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis","volume":"30","author":"Olyaeemanesh","year":"2016","journal-title":"Med. J. Islam Repub. Iran"},{"key":"10.1016\/j.msard.2018.11.001_bib0034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","article-title":"The effect of disease,functional status, and relapses on the utility of people with multiple sclerosis in the UK","volume":"10","author":"Orme","year":"2007","journal-title":"Value Health."},{"key":"10.1016\/j.msard.2018.11.001_bib0035","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","article-title":"No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine","volume":"2","author":"Pakpoor","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.11.001_bib0048","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","article-title":"Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study","volume":"27","author":"Rejdak","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2018.11.001_bib0036","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.11.001_bib0037","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1212\/WNL.54.5.1145","article-title":"Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial","volume":"54","author":"Rice","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.001_bib0038","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet."},{"key":"10.1016\/j.msard.2018.11.001_bib0039","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.11.001_bib0040","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1352458517713668","article-title":"Comparative effectiveness of rituximab relative to IFN-\u03b2 or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry","volume":"24","author":"Spelman","year":"2018","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.11.001_bib0041","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/WCO.0000000000000317","article-title":"Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis","volume":"29","author":"Steinman","year":"2016","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2018.11.001_bib0042","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1352458509103610","article-title":"Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: Results of a 2-year, double-blind, placebo-controlled, crossover study","volume":"15","author":"Stelmasiak","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.11.001_bib0043","series-title":"Importance of upper limb function in advanced multiple sclerosis","author":"Thomson","year":"2016"},{"key":"10.1016\/j.msard.2018.11.001_bib0044","year":"2011"},{"issue":"2","key":"10.1016\/j.msard.2018.11.001_bib0045","article-title":"Mycophenolate mofetil for relapsing-remitting multiple sclerosis","author":"Xiao","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.msard.2018.11.001_bib0046","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.msard.2018.05.010","article-title":"Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine","volume":"24","author":"Yildiz","year":"2018","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818304863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818304863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:47:35Z","timestamp":1761900455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818304863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":48,"alternative-id":["S2211034818304863"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.001","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}